Format

Send to

Choose Destination
Med Sci (Paris). 2018 Dec;34(12):1092-1099. doi: 10.1051/medsci/2018294. Epub 2019 Jan 9.

[Mesenchymal stem cells and regenerative medicine: future perspectives in osteoarthritis].

[Article in French]

Author information

1
IRMB, université de Montpellier, Inserm U1183, 80, avenue Augustin Fliche, 34295 Montpellier, France.
2
IRMB, université de Montpellier, Inserm U1183, 80, avenue Augustin Fliche, 34295 Montpellier, France - Unité d'immunologie clinique et de thérapeutique des maladies ostéoarticulaires, département de rhumatologie, hôpital Lapeyronie, 34000 Montpellier, France.

Abstract

Mesenchymal stromal or stem cells (MSCs) are multipotent adult cells that can be isolated from a variety of adult or neonatal tissues, such as bone marrow, fat tissue, placenta or umbilical cord. A therapy based on MSCs can be justified in osteoarthritis (OA) thanks to their differentiation abilities but mostly, to their paracrine and immunosuppressive properties. Possible therapeutic strategies therefore rely on the articular injection of MSCs suspensions for trophic activity or the implantation of MSCs combined with biodegradable materials for tissue engineering applications. Depending on the mode of administration and behavior after implantation, they can decrease local inflammation, prevent chondrocyte hypertrophy and apoptosis as well as differentiate into cartilage-forming chondrocytes. In this review, we summarize pathophysiological and mechanistic data and discuss perspectives confirming the interest of MSCs as a potential therapeutic strategy in OA.

PMID:
30623767
DOI:
10.1051/medsci/2018294

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center